MedTrace Logo

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

NCT03122496 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2022-06-08

No results posted yet for this study

Summary

The purpose of this study is to test the safety of durvalumab (MEDI4736) and tremelimumab in combination with radiation therapy and find out what effects, if any, this combination has on people, and whether it improves overall survival.

Conditions

  • Metastatic Anaplastic Thyroid Cancer

Interventions

DRUG

durvalumab

Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.

DRUG

tremelimumab

Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.

RADIATION

Stereotactic Body Radiotherapy (SBRT)

SBRT at 9Gy x 3 per standard of care given within 2 weeks after the completion of Cycle 1 of durvalumab (MEDI4736) and tremelimumab

Sponsors & Collaborators

Principal Investigators

  • Nancy Lee, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-25
Primary Completion
2022-06-03
Completion
2022-06-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03122496 on ClinicalTrials.gov